Baseline and dynamic changes in skeletal muscle mass as predictive biomarkers in patients with metastatic renal cell carcinoma treated with Nivolumab
Yazarlar (7)
Doç. Dr. Erdem Özkan Kastamonu Training And Research Hospital, Türkiye
Murathan Koksal
Ankara Bilkent City Hospital, Türkiye
Ankara Bilkent City Hospital, Türkiye
Doç. Dr. Bünyamin ECE Kastamonu Üniversitesi, Türkiye
Prof. Dr. Mustafa Koyun Kastamonu Training And Research Hospital, Türkiye
Ömer Faruk Kuzu Cankiri State Hospital, Türkiye
Doç. Dr. Yusuf Açıkgöz Lokman Hekim Üniversitesi, Türkiye
Efnan Algın
Sağlık Bilimleri Üniversitesi, Türkiye
Sağlık Bilimleri Üniversitesi, Türkiye
| Makale Türü |
Özgün Makale
(SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
|
||
| Dergi Adı | Radiology and Oncology (Q2) | ||
| Dergi ISSN | 1318-2099 Dergi Bilgileri (2025) | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 12-2025 |
| Kabul Tarihi | – | Yayınlanma Tarihi | 01-12-2025 |
| Cilt / Sayı / Sayfa | 59 / 4 / 624–634 | DOI | 10.2478/raon-2025-0065 |
| Makale Linki | https://doi.org/10.2478/raon-2025-0065 | ||
| UAK Araştırma Alanları |
Radyoloji
|
||
| Özet |
| Background Low skeletal muscle mass has been increasingly recognized as a negative prognostic factor in oncology. According to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), sarcopenia is defined as a progressive and generalized skeletal muscle disorder characterized by the loss of muscle strength and muscle mass, which can lead to impaired physical performance. This study aimed to investigate whether baseline low muscle mass and dynamic changes in muscle mass during immunotherapy could predict treatment response and survival in patients with metastatic renal cell carcinoma (mRCC) treated with Nivolumab. Patients and methods This retrospective cohort study included 50 mRCC patients (35 men, 15 women; mean age 59.1 ± 10.2 years) who received Nivolumab between 2019 and 2022 and underwent abdominal computed tomography (CT) before and during … |
| Anahtar Kelimeler |
| computed tomography | low muscle mass | nivolumab | renal cell carcinoma |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 1 |